ARRIVENT BIOPHARMA, INC. Earnings Per Share (Basic)
ARRIVENT BIOPHARMA, INC. (AVBP) reported Earnings Per Share (Basic) of -$1.05 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-12
- ARRIVENT BIOPHARMA, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$1.05.
- ARRIVENT BIOPHARMA, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$0.96.
- ARRIVENT BIOPHARMA, INC. earnings per share, basic for the quarter ending 2025-12-31 was -$0.83.
- ARRIVENT BIOPHARMA, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$0.83.
- ARRIVENT BIOPHARMA, INC. earnings per share, basic for fiscal 2025 was -$4.32.
- ARRIVENT BIOPHARMA, INC. earnings per share, basic for fiscal 2024 was -$2.56.
- ARRIVENT BIOPHARMA, INC. earnings per share, basic for fiscal 2023 was -$32.38.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.05 10-Q · filed 2026-08-12 | -$2.01 10-Q · filed 2026-08-12 | -$2.85 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$3.69 derived: net income ÷ weighted average shares · filed 2026-08-12 |
| 2026-03-31 | -$0.96 10-Q · filed 2026-05-11 | -$1.79 derived: net income ÷ weighted average shares · filed 2026-05-11 | -$2.63 derived: net income ÷ weighted average shares · filed 2026-05-11 | -$3.52 derived: net income ÷ weighted average shares · filed 2026-08-12 |
| 2025-12-31 | -$0.83 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$1.66 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$2.55 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$4.32 10-K · filed 2026-03-05 |
| 2025-09-30 | -$0.83 10-Q · filed 2025-11-10 | -$1.73 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$3.54 10-Q · filed 2025-11-10 | -$4.19 derived: net income ÷ weighted average shares · filed 2026-08-12 |
| 2025-06-30 | -$0.90 10-Q · filed 2026-08-12 | -$2.78 10-Q · filed 2026-08-12 | -$3.40 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$4.02 derived: net income ÷ weighted average shares · filed 2026-08-12 |
| 2025-03-31 | -$1.90 10-Q · filed 2026-05-11 | -$2.51 derived: net income ÷ weighted average shares · filed 2026-05-11 | -$3.13 derived: net income ÷ weighted average shares · filed 2026-05-11 | -$3.78 derived: net income ÷ weighted average shares · filed 2026-05-11 |
| 2024-12-31 | -$0.61 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$1.22 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$1.88 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$2.56 10-K · filed 2026-03-05 |
| 2024-09-30 | -$0.61 10-Q · filed 2025-11-10 | -$1.27 derived: net income ÷ weighted average shares · filed 2025-11-10 | -$1.95 10-Q · filed 2025-11-10 | -$3.42 derived: net income ÷ weighted average shares · filed 2025-11-10 |
| 2024-06-30 | -$0.65 10-Q · filed 2025-08-11 | -$1.34 10-Q · filed 2025-08-11 | -$2.96 derived: net income ÷ weighted average shares · filed 2025-08-11 | -$4.69 derived: net income ÷ weighted average shares · filed 2025-08-11 |
| 2024-03-31 | -$0.70 10-Q · filed 2025-05-12 | -$2.78 derived: net income ÷ weighted average shares · filed 2025-05-12 | -$5.24 derived: net income ÷ weighted average shares · filed 2025-05-12 | -$9.22 derived: net income ÷ weighted average shares · filed 2025-05-12 |
| 2023-12-31 | -$7.81 derived: net income ÷ weighted average shares · filed 2025-03-03 | -$13.38 derived: net income ÷ weighted average shares · filed 2025-03-03 | -$23.42 derived: net income ÷ weighted average shares · filed 2025-03-03 | -$32.38 10-K · filed 2025-03-03 |
| 2023-09-30 | -$5.52 10-Q · filed 2024-11-14 | -$15.61 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$24.69 10-Q · filed 2024-11-14 | |
| 2023-06-30 | -$10.79 10-Q · filed 2024-08-14 | -$20.60 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | -$9.45 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |